SCHEMBL23728540

SCHEMBL23728540

CCc1cnc2c(C(=O)O)cnn2c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE2A O00408 9/20 0.43
ALDH1A1 P00352 4/20 0.42
KDM4E B2RXH2 4/20 0.42
TDP1 Q9NUW8 3/20 0.42
NR4A3 Q92570 1/20 0.41
HPGD P15428 1/20 0.40
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
RXFP1 Q9HBX9 1/20 0.40
GABRP O00591 1/20 0.38
GABRD O14764 1/20 0.38
GABRA1 P14867 1/20 0.38
GABRB1 P18505 1/20 0.38
GABRG2 P18507 1/20 0.38
GABRB3 P28472 1/20 0.38
GABRA5 P31644 1/20 0.38
GABRA3 P34903 1/20 0.38
GABRA2 P47869 1/20 0.38
GABRB2 P47870 1/20 0.38
GABRA4 P48169 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12505460 0.85 IRAK4 (0.43) PDE2AALDH1A1KDM4ETDP1MEN1
SCHEMBL23728526 0.85 ALDH1A1 (0.56) PDE2AALDH1A1KDM4EHPGDKMT2A
SCHEMBL359027 0.83 KDM4E (0.58) PDE2AALDH1A1KDM4ETDP1HPGD
SCHEMBL18208530 0.81 PDE2A (0.45) PDE2AALDH1A1KDM4ETDP1MEN1
SCHEMBL358957 0.80 KDM4E (0.49) PDE2AALDH1A1KDM4ETDP1MEN1
SCHEMBL310126 0.78 PDE2A (0.59) PDE2AALDH1A1KDM4ETDP1PDE3A
SCHEMBL18208918 0.78 ALDH1A1 (0.49) PDE2AALDH1A1KDM4ETDP1HPGD
SCHEMBL14033681 0.77 PDE2A (0.39) PDE2AALDH1A1KDM4ETDP1MEN1
SCHEMBL31547085 0.76 SMN1; SMN2 (0.47) ALDH1A1KDM4ENR4A3HPGDMEN1
SCHEMBL12505413 0.76 IRAK4 (0.43) PDE2AALDH1A1KDM4ETDP1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230122219-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-04-20 US disclosed
US-20230122219-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-04-20 US disclosed
EP-4100004-A1 IRAK DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2022-12-14 EP disclosed
WO-2021158634-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2021-08-12 WO disclosed
WO-2021158634-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2021-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230122219-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 PDE2A 3378/4885ALDH1A1 2776/4885KDM4E 190/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.